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Abstract
Background: Hyperhomocysteinemia is known as an independent risk factor of atherosclerosis, but the
probable role of hyperhomocysteinemia in premature Coronary Artery Disease (CAD) is not well studied.
The aim of this study was to assess the role of hyperhomocysteinemia, folate and Vitamin B12 deficiency
in the development of premature CAD.
Methods: We performed an analytical case-control study on 294 individuals under 45 years (225 males
and 69 females) who were admitted for selective coronary angiography to two centers in Tehran.
Results: After considering the exclusion criteria, a total number of 225 individuals were enrolled of which
43.1% had CAD. The mean age of participants was 39.9 +/- 4.3 years (40.1 +/- 4.2 years in males and 39.4
+/- 4.8 years in females). Compared to the control group, the level of homocysteine measured in the
plasma of the male participants was significantly high (14.9 +/- 1.2 versus 20.3 +/- 1.9 micromol/lit, P =
0.01). However there was no significant difference in homocysteine level of females with and without CAD
(11.8 +/- 1.3 versus 11.5 ± 1.1 micromol/lit, P = 0.87). Mean plasma level of folic acid and vitamin B12 in
the study group were 6.3 +/- 0.2 and 282.5 +/- 9.1 respectively. Based on these findings, 10.7% of the study
group had folate deficiency while 26.6% had Vitamin B12 deficiency. Logistic regression analysis for
evaluating independent CAD risk factors showed hyperhomocysteinemia as an independent risk factor for
premature CAD in males (OR = 2.54 0.95% CI 1.23 to 5.22, P = 0.01). Study for the underlying causes of
hyperhomocysteinemia showed that male gender and Vitamin B12 deficiency had significant influence on
incidence of hyperhomocysteinemia.
Conclusion: We may conclude that hyperhomocysteinemia is an independent risk factor for CAD in
young patients (bellow 45 years old) – especially in men -and vitamin B12 deficiency is a preventable cause
of hyperhomocysteinemia.
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Background
Homocysteine is a sulfhydryl containing amino acid pro-
duced by demethylation of an essential amino acid
(methionine) [1]. Methylation of homocysteine, cata-
lyzed by methionine synthetase produces methionine.
This enzyme needs vitamin B12 as a co-factor. Homo-
cysteine can also change to cystathionine through the
action of the Cystathionine-B-Synthetase (CBS) enzyme
[2,4].In humans, vitamin B12 acts as a coenzyme while
folic acid provides the methyl essential for the reactions to
take place [2,4]. Therefore, folic acid and vitamin B12
deficiency can cause reduction in methylene tetrahydro-
folate reductase (MTHFR) activity, leading to decrease in
methyonine synthesis and homocysteine accumulation
[3,5] (Figure 1).
Except in cases of severe hyperhomocysteinemia (plasma
total homocysteine (tHcy) > 100 μmol/lit), usually due to
metabolic disorders of methyonine metabolism, mild or
moderate cases of hyperhomocysteinemia (tHcy > 15
μmol/lit), prevalent in the general population, can be the
result of dietary deficiency of factors such as vitamin B12
and folic acid [5-7]. Other conditions such as polymor-
phism in the coding gene of MTHFR, consumption of
folate antagonists such as carbamazepine and methotrex-
ate and finally disorders of homocysteine metabolism
during hypothyroidism and renal failure can also cause
hyperhomocysteinemia [8,9]. Recent studies beside dem-
onstrate that diabetes, hypertension, hypercholestero-
lemia, cigarette smoking and positive family history well
known risks in the atherosclerosis phenomena, high
plasma level of homocysteine also acts as an independent
risk factor of atherosclerosis and coronary artery dis-
ease[10-12].
Meanwhile, we do not have sufficient data regarding the
role of hyperhomocysteinemia in development of prema-
ture CAD and this question needs further investigations
[13,14]. Here we should mention that, in most studies,
premature CAD is defined as CAD in men under 55 or
women less than 65 years old [15]. However, in the Fram-
ingham risk stratification table and certain other investi-
gations, the onset of ascending cardiovascular disease in
men and women was estimated between the ages of 40–
Metabolism of methionine/homocysteine [38] Figure 1
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45 years [16]. Based on the above mentioned points, we
decided to perform this study in patients less than 45
years in order to have a better evaluation of risk factors in
premature CAD. Therefore in the present study, increasing
age is not a prominent factor.
In addition to CAD development, high plasma levels of
homocysteine have a relation with the incidence of several
neurologic disorders such as congenital neural tube
defect, Alzheimer's disease and suspicious carcinogenic
potentials [17-19].
This study was performed to assess the role of homo-
cysteine, folic acid and vitamin B12 (as probable causes of
hyperhomocysteinemia) in the occurrence of premature
CAD while considering other known risk factors of CAD.
Methods
This case-control analytical study was performed in a
group of 294 participants (225 male and 69 female)
including consecutive patients aged less than 45 years old,
who underwent selective coronary angiography into two
medical and educational centers in Tehran. From the 294
patients included in this study: 144 were referring angina
(56 stable angina and 88 unstable angina); 41 had a pre-
vious myocardial infarction; 65 had a positive ergometric
test and 44 had a positive scintigraphy test. The sample
population was stratified in patients with CAD (127) and
normal (167) groups. There were two sources for data col-
lection. Some data were gathered by interview and filling
a questionnaire covering all personal data and medical
history. This questionnaire was designed based on stand-
ard Rose questionnaire for anginal pain, known CAD risk
factors and confounding factors.
The second source of data was lab exams [performed for
homocysteine, folic acid, vitamin B12, triglyceride, and
cholesterol, low density lipoprotein (LDL) and high den-
sity lipoprotein (HDL)] and the results of selective coro-
nary angiography. We excluded patients with myocardial
infarction in the last 6 weeks, those who had taken any
medication containing vitamin B12 or folic acid and N-
Acetyl Cysteine (NAC) within 6 weeks of enrollment,
those suffering from hypothyroidism ,anemia (hemo-
globin<12 g/dl) and creatinine levels equal or greater than
1.5 mg/dl plus any features of chronic renal failure. By
applying these criteria, 69 participants (46 males and 23
females) were excluded from the study.
Laboratory analyses
Blood samples were withdrawn from patients after an
overnight fast, and the plasma were put in a cooled con-
tainer and immediately carried to the "Massoud" labora-
tory, where the plasma was separated within 1 hour of
sampling by centrifugation (20 min, RT, at 2000 RPM)
and aliquots were stored at -70°C until analysis. Plasma
level of homocysteine was determined by high perform-
ance liquid chromatography (HPLC) method, coupled
with fluorescence detector and plasma level of folic acid
and vitamin B12 by Radio immunoassay (RIA). The
serum level of lipids and lipoproteins were determined by
calorimetric method. Folic acid levels less than 2.2 ng/ml
and vitamin B12 levels less than 175 pg/ml were classified
as folate and B12 deficiency, respectively.
Definitions of risk factors
The traditional or classical coronary risk factors include:
(1) diabetes mellitus (positive past history of diabetes and
new diabetics, fasting plasma glucose ≥ 120 mg/dl or two
hours after glucose load ≥ 200 mg/dl); (2) hypertension
(positive past history of hypertension and new hyperten-
sives, systolic blood pressure ≥ 140 mmHg or diastolic
blood pressure ≥ 90 mmHg, based on the average of two
or more readings on two or more occasions after initial
screening); (3) Hyperlipidemia (total cholesterol> 250
mg/dl, LDL > 160 mg/dl or if the patient was on lipid-low-
ering therapy); (4) smoking (Regularly using tobacco for
the last 6 months); and (5) family history of CAD (one or
more family member, including parents, brothers and sis-
ters, with documented CAD).
Statistical analysis
After collection of crude necessary data, these data were
statistically analyzed by statistical analysis system (SAS)
software for windows 9.1. We used chi-square and t-test to
compare qualitative variables and quantitative variables,
respectively. Logistic regression analysis was used for
detecting independent variables. The differences were
considered significant if P value was less than 0.05.
Ethical consideration
The committee for medical ethics of the Tehran Heart
Center approved the study. Each participant signed an
informed consent form before completing the question-
naire.
Results
A total number of 225 participants were enrolled from
which 179 (79.6%) were male and 46 (20.4%) were
female. All participants were under 45 years old.
Considering results of coronary angiogram, 97 partici-
pants (43.1%) had premature coronary artery disease of
which 86 patients (88.7%) were male and 11 (11.3%)
were female ;128 participants (56.9%) were free of signif-
icant CAD of which 93 (72.7%) were male and 35
(27.3%) were female that stratified in control group. In
patients with significant CAD; 32 (33%) had single vessel
disease, 37 (38.2%) two vessel disease and 28 (28.8%)
had three vessel disease.BMC Cardiovascular Disorders 2006, 6:38 http://www.biomedcentral.com/1471-2261/6/38
Page 4 of 7
(page number not for citation purposes)
The mean age of the study group was (40.1 ± 4.2) years in
males and (39.4 ± 4.8) in females. No significant differ-
ence was noted between the patient and control group in
this regard. Major CAD risk factors are compared between
controls and patients in Table 1. Significant differences
were noted for male gender, diabetes mellitus and hyper-
lipidemia.
The mean serum level of homocysteine was (16.6 ± 1.01
μmol/lit) in the study group and was significantly higher
in males (17.9 ± 1.2 μmol/lit) compared to females (11.5
± 0.9 μmol/lit) (P < 0.01). The mean plasma level of
homocysteine in patients (19.3 ± 1.7 μmol/lit) was signif-
icantly higher than the control group (13.9 ± 0.9 μmol/lit)
(P < 0.005). Considering the sex factor, a similar relation-
ship was present in male participants (P < 0.01) but not in
females (P = 0.87) (Table 2).
In order to evaluate the risk of hyperhomocysteinemia for
premature CAD in the context of other known CAD risk
factors such as diabetes mellitus, hypertension, hyperlipi-
demia, lipoprotein disorders, positive family history and
cigarette smoking, logistic regression test was performed.
Results showed that the risk of premature CAD in those
participants with a homocysteine plasma level of more
than 15 μmol/lit was 2.4 times more than others (OR =
2.42, 95% CI: 1.28–4.56: P = 0.007) (Table 3).
Logistic regression test in males with and without hyper-
homocysteinemia compared to total subjects showed sim-
ilar results in effect of hyperhomocysteinemia on
development of CAD (OR = 2.54, 95% CI: 1.23–5.22: P =
0.01) while in females there was no increased chance for
premature CAD in individuals with hyperhomocysteine-
mia. However, prevalence of premature CAD was higher
in females with hyperhomocysteinemia (above 15 μmol/
lit) than who did not have hyperhomocysteinemia
(42.9% versus 20.5%). The role of other known risk fac-
tors of CAD in increasing the risk of premature CAD is
also demonstrated in Table 3.
We studied the relation between hyperhomocysteinemia
and plasma level of folic acid, vitamin B12, male gender,
increasing age, cigarette smoking, diabetes mellitus and
hypertension. Mean plasma level of folic acid in the study
group was 6.33 ± 0.29 ng/ml (5.6 ± 0.2 ng/ml in males
and 8.8 ± 0.7 ng/ml in females). Mean plasma level of
vitamin B12 was 282.5 ± 9.1 pg/ml (283.8 ± 10.5 pg/ml
in males and 277.5 ± 18.6 pg/ml in females). Therefore,
10.7% of the study group (24 participants) had folic acid
deficiency (13.1% of male participants and 2% of
females). Also 24.3% (55 participants) had vitamin B12
deficiency (26.6% of males and 16.3% of females).
Although generally speaking there is a reverse relationship
between plasma level of homocysteine and folic acid level
(Pearson correlation coefficient = -0.148, P = 0.02) or vita-
min B12 (Pearson correlation coefficient = -0.22, P =
0.001), the logistic regression test for the study group
showed that male sex (OR = 3.87, 95% CI : 1.57–9.50, P
= 0.003) and vitamin B12 deficiency (OR = 2.06, 95% CI
: 1.06–3.98 : P < 0.0001) were two factors that caused sig-
nificant increase in homocysteine levels.
Other factors such as cigarette smoking, increasing age,
diabetes mellitus and hypertension did not have any sta-
tistically significant role in hyperhomocysteinemia
(tHcy>15 μmol/lit). Although the mean plasma level of
homocysteine in cigarette smokers (17.5 ± 1.4 μmol/lit)
was higher than non-smokers (14.9 ± 1.2 μmol/lit), this
was not statistically significant (P = 0.16). Mean plasma
level of homocysteine in hypertensive individuals was not
Table 1: Characteristics of study population
Risk factor Case group Control group P value
Age (year ± SD) 41.01 ± 3.13 39.1 ± 4.94 0.05
Male gender, n (%) 86(88.7) 93(72.6) 0.01
Family history, n (%) 31(31.9) 34(26.5) 0.75
Hypertension, n (%) 24(24.7) 21(16.4) 0.18
Diabetes mellitus, n (%) 13(13.4) 3(0.02) 0.02
Smoking, n (%) 57(58.7) 57(44.5) 0.36
Hyperlipidemia, n (%) 39(40.2) 25(19.5) 0.01
Laboratory data
Triglyceride (mg/dl) 194.68 ± 8.5 177.21 ± 12.4 0.25
Cholesterol (mg/dl) 209.8 ± 4.7 189.34 ± 4.0 0.77
LDL (mg/dl) 132.1 ± 4.1 113.33 ± 2.9 0.16
HDL (mg/dl) 37.7 ± 0.83 41.25 ± 0.92 0.02
Homocysteine (μmol/L) 1.7 ± 19.3 0.9 ± 13.9 0.00
SD, standard deviation; LDL, low density lipoprotein; HDL, high density lipoproteinBMC Cardiovascular Disorders 2006, 6:38 http://www.biomedcentral.com/1471-2261/6/38
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significantly different from normotensives (16.2 ± 2.6
μmol/lit versus 16.3 ± 0.9 μmol/lit, P = 0.97). The differ-
ences in diabetic and non diabetic individuals were also
non significant (13.6 ± 1.4 μmol/lit versus 16.4 ± 1.02
μmol/lit, P = 0.44). No significant difference in plasma
homocysteine level was observed in either of age groups
(above and bellow 35 years) (P = 0.1).
Discussion
In the present study, the prevalence of hyperhomo-
cysteinemia in patients with premature CAD was 47.4%.
American Heart Association (AHA) reported a prevalence
of 12 to 47% in 1999 for patients with CAD [20]. The
results of our study show that plasma level of homo-
cysteine in individuals with premature CAD are signifi-
cantly higher than participants without CAD (19.3 ± 1.7
μmol/lit versus 13.9 ± 0.9 μmol/lit, P = 0.005) and plasma
homocysteine levels of more than 15 μmol/lit (hyperho-
mocysteinemia by definition) were correlated with higher
risk of premature CAD. (OR = 2.42, 95% CI: 1.28–4.56, P
= 0.007). However, after considering sex as a factor and
repeating the statistical tests for subgroups, this conclu-
sion was only valid for male participants. (OR = 2.54,
95% CI: 1.23–5.22; P = 0.01) and there was no increased
risk for premature CAD in women with hyperhomo-
cysteinemia. Many studies have shown that elevated total
homocysteine concentration is an independent risk factor
for cardiovascular diseases. Guo et al in Fokui university
(Japan) showed that the plasma level of homocysteine in
patients with premature CAD was significantly higher
than the control group (15.0 ± 5.7 μmol/lit versus 10.3 ±
5.1 μmol/lit, P < 0.01) [21].
Pinto et al in Bellvitge hospital (Spain) also found a cor-
relation between high plasma level of homocysteine and
premature CAD (P < 0.001; OR = 3.2). In their study
hyperhomocysteinemia was presented as a risk factor for
premature CAD [22].
Lolin et al (China) showed that in patients with prema-
ture CAD, plasma levels of homocysteine was significantly
higher than normal participants (6.41 μmol/lit versus
5.35 μmol/lit, P = 0.042) [23]. Clarke et al at Adelayde
hospital (Ireland) also found quite similar results (OR =
3.2; P = 0.002) [24].
Although, in none of the above mentioned studies was
there any difference between males and females in this
regard, Foody et al (Cleveland – USA) showed that despite
the presence of a correlation between hyperhomo-
cysteinemia and premature CAD in males (OR = 1.93; P =
0.05) no such correlation was noted in females (OR =
1.06; P = 0.89) which resembles our findings [25].
Based on the results of our study and other previous stud-
ies it seems that hyperhomocysteinemia is a risk factor for
premature CAD in men, but not proven so in women. A
Correlation between plasma levels of homocysteine,
severity of CAD and number of involved vessels was stud-
ied and no significant correlation was found. Brilakis et al
have also studied the correlation between plasma level of
homocysteine and angiographic findings in patients with
CAD and found no significant correlation [26].
Plasma level of homocysteine in male participants was
significantly higher than females (17.9 ± 1.2 μmol/lit ver-
sus 11.5 ± 5.9 μmol/lit, P = 0.01). Logistic regression anal-
ysis yeilded the same results, meaning male sex was an
effective factor in plasma level of homocysteine in our
study group (OR = 3.87, 95% CI: 1.57–9.5; P = 0.003).
Table 3: Multivariate logistic regression analysis for development of coronary artery disease
Risk factors Odds ratio (OR) Confidence interval 95% (CI) P value
Male gender 3.05 1.28 – 7.27 0.012
Diabetes mellitus 4.91 1.18 – 20.4 0.029
Hyperlipidemia 2.29 1.16 – 4.53 0.017
HDL 2.05 1.09 – 3.84 0.026
Hyperhomocysteinemia 2.42 1.28 – 4.56 0.007
HDL, high density lipoprotein
Table 2: Plasma homocysteine level in study population
Number (%) homocysteine (μmol/L) P value
Male Control 93(52) 14.9 ± 1.2 0.01
Case 86(48) 20.3 ± 1.9
Female Control 35(76) 11.5 ± 1.1 0.87
Case 11(24) 11.8 ± 1.3BMC Cardiovascular Disorders 2006, 6:38 http://www.biomedcentral.com/1471-2261/6/38
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Like wise, Jucques et al(Boston- USA) showed that the
mean plasma level of homocysteine in men was 11%
more than women (P < 0.001). This difference could be
having several explanations [27]. First; sex hormones have
effects on methionine metabolism; second, the level of
creatinine is higher in men; third, the musculoskeletal sys-
tem of men is usually more developed and has a larger
volume and mass compared to women; fourth, plasma
level of folic acid and vitamin B12 is different between
men and women [28]. But some studies do not confirm
these results [29].
In our study, the prevalence of hyperhomocysteinemia
was higher than other populations. It could be due to geo-
graphical variations, racial and ethnic differences [30],
genetic causes, different lifestyle, and inadequate intake of
B vitamins and folate, inaccurate cooking of vegetables
and not implementing fortification of grain products with
folic acid in our country. A low daily intake of vitamin
B12 and folic acid could be an eventual cause of hyperho-
mocysteinemia in our study population. Prolonged cook-
ing of vegetables may destroy up to 90% of folate content
[31]. Candidate genes can regulate plasma homocysteine
concentrations, especially methylene tetrahydrofolate
reductase (MTHFR) and cystathionine-β-synthase (CBS)
genes. Recent studies have shown the importance of DNA
polymorphisms in the genes for enzymes involved in
homocysteine metabolism [32].
Based on results of the present study, the prevalence of
folic acid deficiency was 10.7% (13.1% in men and 2% in
women) while vitamin B12 deficiency had a rate of 24.4%
(26.6% in men and 16.7% in women). This deficiency
(especially in vitamin B12) is considerable. Logistic
regression tests demonstrate that vitamin B12 deficiency
was an effective factor in hyperhomocysteinemia in our
study group (OR = 2.06, 95% CI: 1.06–3.98; P < 0.0001)
which resembles Jucques et al findings [27]. Despite
reports about the role of cigarette smoking, diabetes and
hypertension in hyperhomocysteinemia, our study did
not show such a relation [33-35]. One of our study limi-
tations is the smaller sample size of female participants in
comparison to males. This limitation causes our inability
to precisely evaluate the role of hyperhomocysteinemia in
young females with CAD.
The present study is one of the few studies in which the
control group is chosen precisely and based on angio-
graphic results, while in most of studies, lack of CAD
symptoms and signs have been the inclusion criteria for
the control group [36,37].
Conclusion
We may conclude that hyperhomocysteinemia is an inde-
pendent risk factor for CAD in young patients (bellow 45
years old) (especially in men) and vitamin B12 deficiency
is a preventable cause of hyperhomocysteinemia.
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